Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribosomal protein L21 pseudogene 29 (RPL21P29) is a processed pseudogene related to the ribosomal protein L21. Pseudogenes derive from functional genes but typically lack protein-coding capacity and do not produce functional protein products. RPL21P29 exists in the genome but is not transcribed or translated into a protein, and is not considered to have any therapeutic or biological role. Its identification as a “target” is likely incorrect; instead, it is a genetic sequence of interest only for genomic or evolutionary studies. To summarize: RPL21P29 is a pseudogene with no known function, disease association, or therapeutic relevance. Any reference to it as a drug target, receptor, enzyme, or functional protein is incorrect. The canonical active form is ribosomal protein L21 (RPL21), which is a bona fide ribosomal protein and not a pseudogene[1][3][2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L21 pseudogene 29 (RPL21P29).